Among the more than 2,600 clinical trials testing the most successful type of cancer immunotherapy, only 89, or about 3%, target pancreatic cancer, according to a new analysis unveiled Sunday by the nonprofit Cancer Research Institute.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,